Between 10 and 30% of patients undergoing percutaneous coronary intervention (PCI) have left ventricular (LV) dysfunction. We investigate the association between LV function on early and late mortality outcomes in a national 'real-world' cohort undergoing PCI in the elective and acute coronary syndrome setting through analysis of the British Cardiovascular Intervention Society (BCIS) data set.
Introduction
Between 10 and 30% of patients undergoing percutaneous coronary intervention (PCI) have left ventricular (LV) dysfunction 1 -4 yet individuals with significant LV dysfunction are often excluded from contemporary randomized controlled trials. 5, 6 Patients with LV dysfunction undergoing PCI tend to be older, with more co-morbid conditions such as renal failure and diabetes and have more extensive and † M.A.M. and S.G.A. contributed equally to this work.
complex disease than those with good LV function. 7, 8 The adverse demographic features commonly found in patients with impaired LV function are known to contribute to unfavourable outcomes following PCI and LV function features strongly as a predictor of adverse outcomes in contemporary risk stratification scores for patients undergoing PCI. 9, 10 Previous studies have suggested that impaired LV function may predict mortality 1,3,4,10 and major adverse cardiovascular events (MACE) outcomes 1, 7 following PCI.
However, many of these studies that have specifically assessed the impact of LV function on outcomes following PCI have limited their observations to patients undergoing PCI in the elective setting 1, 8, 11 and often only report the impact of LV dysfunction on in-hospital outcomes 8 with very few reporting outcomes beyond 1 year. 3, 4 Furthermore, several previous reports studied the impact of LV function in patients who underwent PCI in the late 1990s and so the outcomes reported may not be applicable to contemporary cohorts. 1, 8 In addition, the prognosis of patients with impaired ventricular function has been altered favourably over recent years because of better pharmacological and device therapies. More contemporary reports are based on cohorts from randomized controlled trials, hence may not be representative of real-world practice. 3 We report the association between LV function on early and late mortality outcomes in a national 'real-world' UK-based cohort undergoing PCI in both the elective and acute coronary syndrome (ACS) setting through analysis of the British Cardiovascular Intervention Society (BCIS) data set.
Methods
The British cardiovascular intervention society database
The British Cardiovascular Intervention Society (BCIS) collects PCI data relating to the nationwide practice of PCI in the UK. 12 The data are collected via the Central Cardiac Audit Database under the auspices of the National Institute of Cardiovascular Outcomes Research (http://www. ucl.ac.uk/nicor/). In 2011, 99.4% of all PCI procedures performed in National Health Service (NHS) hospitals in England and Wales had been entered into the database (web reference www.bcis.org.uk/). The BCIS-NICOR database records clinical, procedural, and outcome information with a total of 113 variables As of December 2011 there were 460 124 PCI records in the BCIS database, with 80 000 new records being added each year. Mortality tracking is undertaken by the Medical Research Information Service (MRIS) using patients' NHS number that provides a unique identifier for any person registered with the NHS in England and Wales.
Study definitions
Percutaneous coronary intervention procedures undertaken in patients in the UK between 1 January 2006 and 31 December 2011 were analysed. Left ventricular function is recorded in the BCIS database as categorical variables as follows: good LV function (ejection fraction .50%), moderately impaired LV Function (ejection fraction 30 -49%), or poor LV function (ejection fraction ,30%). The primary outcomes examined were 30-day, 1-, and 5-year mortality. The mortality data for each procedure were validated against Office for National Statistics records-the statutory deaths register of the UK. Major adverse cardiovascular and cerebrovascular events (MACCE) was defined as a composite of in-hospital mortality, myocardial infarction (MI) or re-infarction, target vessel revascularization, and cerebrovascular events. In-hospital major bleeding complications were defined as gastrointestinal bleed, intracerebral bleed, retroperitoneal haematoma, blood or platelet transfusion, or an arterial access site complication requiring surgery.
Statistical analyses
Anthropometric data are expressed as arithmetic mean + SD. The normal distribution of the continuous variables was examined with Shapiro-Wilk's test with the aim to log transform if relevant skewed varaiables were identified. Comparison of means was by ANOVA. Categorical variables were presented as a percentage of data available. The Wilcoxon-signed rank sum test, ANOVA, or x 2 test were used to compare proportions for non-parametric data. Tests for linear trend used Chi-squared models.
The primary outcome was all-cause mortality. Patients were followed from the date of the procedure to death or study censor date (26 June 2013) . Separate analyses were performed on mortality within 30 days, 1 year, and 5 years of intervention. Crude mortality rates were determined from the number of failures (deaths) as a proportion of persontime (an estimate of the actual time-at-risk in years that all person contribute) and are presented per 1000 person-years. We estimated hazard ratios (HR) for all-cause mortality at 30-day, 1 year, or 5 years using Cox proportional hazard regression models. Multivariate adjustment included the following variables: history of diabetes, previous PCI, CABG, previous MI, gender, arterial complications, family history of IHD, NYHA class, smoking, circulatory support, Q-wave on ECG, multi-vessel disease, age, pre-procedural shock, and circulatory support [with intra aortic balloon pump (IABP)]. Survival was analysed using Kaplan-Meier survival curves with the log-rank test. In separate multivariable models, we removed patients with pre-procedural shock and circulatory support.
We used propensity score methods with nearest neighbour matching to control for potentially confounding factors. A propensity score was estimated for the primary clinical outcome (mortality) within each clinical syndrome-elective, NSTEMI, or STEMI given the following variables: left ventricular ejection fraction (LVEF), age, sex, IABP use, ventilation required, cardiogenic shock, peripheral vascular disease, hypertension, cholesterol, GP2b/3a inhibitor use, cholesterol, history of type 2 diabetes, previous MI, CABG, PCI, stroke, access site employed, and their interaction terms. Mahalanobis distance matching with the propensity score as the distance matrix was then undertaken. Standardized differences between groups were estimated to assess the balance achieved by matching. A baseline characteristic was considered to be well balanced if the standardized difference was ,0%.
We used inverse probability weight analyses to account of the issue of missingness. We performed a complete case analysis using Cox regressions, but weighted the complete cases by the inverse of their probability of having data observed (i.e. not being missing). Those who had a small chance of being observed are therefore given increased weight, to compensate for those similar subjects who are missing.
All statistical analyses were performed with the statistical package Stata/MP version 13 (Stata Corp, TX, USA).
Results
A total of 460 124 PCI procedures were undertaken in the UK between 1 January 2006 and 31 December 2011 in which LV function was documented in 230 464 (50.1%) procedures ( Figure 1A) . A total of 160 687 (69.7%) patients had good LV function (ejection fraction .50%), 56 922 (24.7%) patients had moderately impaired LV function (ejection fraction 30-49%), while the remaining 12 855 (5.6%) patients had poor LV function (ejection fraction ,30%). Baseline clinical demographics are presented in Table 1 and baseline clinical Impact of LV function on PCI outcomes characteristics comparing patients in which LV function was documented with those in whom it was missing are presented in Supplementary material online, Table S1 . Patients with good LV function were younger, had a lower prevalence of diabetes and were less likely to have undergone PCI in the context of an ACS than patients with either moderately impaired or poor LV function. Table 2 illustrates procedural characteristics. Figure 1B illustrates secular trends in syndrome for which PCI was undertaken over time, whereas Figure 2A illustrates secular trends in LV function over time and trends were observed to vary over time (Chi-squared test for trend P , 0.0001 for each category. Figure 2B illustrates the Kaplan-Meier unadjusted survival curves for patients with good, moderately impaired, and poor LV function undergoing PCI. It can be seen that patients with both moderately impaired (HR: 1.90, 95% CI: 1.84 -1.96; P , 0.0001) and poor LV function (HR: 5.44, 95% CI: 5.25-5.64; P , 0.0001) have significantly worse survival than those patients with good LV function. In inverse probability weighting (IPW) Cox regression models, the estimated HR for moderately impaired and poor LV function vs. good LV function was similar (HR: 1.89, 95% CI: 1.83-1.95; P , 0.0001 and HR: 5.28, 95% CI: 5.09-5.48; P , 0.0001). Unadjusted 30-day mortality was 812/160 687 (0.5%) in patients with good LV function, 1153/56 922 (2.0%) in those with moderate LV function and 1281/12 855 (9.96%) in those with poor LV function (P , 0.0001). Table 3 illustrates the un-adjusted 30-day through to 5-year mortality rates and crude mortality rates in person-years for each category of LV function. Supplementary material online, Table S3 illustrates un-adjusted 30-day to 5-year mortality rates and crude mortality rates in cohort where LV function was documented (230 464 patients) and in those patients where LV function data were missing (229 660 patients). Worsening LV function was associated with adverse outcomes at 30 days. Multivariate stepwise cox regression analysis adjusted for baseline procedural and demographic characteristics demonstrated an increase in 30-day mortality risk for patients undergoing PCI in patients with moderately impaired LV function (HR: 2.91; 95% CI: 2.43-3.49, P , 0.0001) and poor LV function (HR: 7.25; 95% CI: 5.87-8.96, P , 0.0001) compared with those patients with good LV function. It can be seen in the complete case analysis of the cohort that even when patients presenting with cardiogenic shock or requiring circulatory support were removed from the analysis, LV function remained associated with 30-day mortality ( Table 4) . Repeating these analyses in separate analyses using the IPW and propensity score matching cohorts revealed similar results (Supplementary material online, Table S4A and B). In hospital, MACCE occurred in 2121/160 567 (1.3%) of patients with good LV function, 1647/56 873 (2.7%) of patients with moderately impaired LV function and 1387/12 843 (10.9%) of patients with poor LV function (P , 0.0001). Multivariate Cox regression analysis adjusted for baseline procedural and demographic characteristics demonstrated an increased risk for in-hospital MACCE for patients with moderately impaired (OR: 1.87 95% CI: 1.71-2.04; P , 0.0001) and poor LV function (OR: 7.41 95% CI: 6.73-8.15; P , 0.0001), respectively, compared with good LV function. In hospital major bleeding events occurred in 770/160 567 (0.5%) of patients with good LV function, 404/56 873 (0.7%) patients with moderately impaired LV function and 186/12 843 patients with poor LV function (1.5%); P , 0.0001. Multivariate Cox regression analysis adjusted for baseline procedural and demographic characteristics demonstrated an increased risk for in-hospital major bleeding for patients with moderately impaired (OR: 1.19 95% CI: 1.01-1.39; P ¼ 0.035) and poor LV function (OR: 2.11 95% CI: 1.69-2.63; P , 0.000); Good LV function as a comparator.
The influence of LV function on mortality outcomes across the elective and acute coronary syndromes [non-ST elevation myocardial infarction/unstable angina (NSTEMI/UA) and ST-elevation myocardial infarction (STEMI)] was examined. Table 5 presents clinical demographics across the three cohorts. Patients presenting with STEMI were younger and less likely to be diabetic than those patients undergoing PCI for NSTEMI or elective indications, while elective PCI patients were more likely to have good LV function than either the NSTEMI or STEMI groups. Figure 3A -C illustrates Kaplan -Meier curves for survival across the three syndromes by each of the different LV function categories. It can be seen that across all three syndromes, both moderately impaired and poor LV function have significantly worse survival than those patients with good LV function. Furthermore, there appears to be a differential association between LV function and mortality across the syndromes, particularly for patients with poor LV function whose impact on mortality increased from the elective setting to UA/NSTEMI setting through to the STEMI setting.
Unadjusted 30-day, 1-, and 5-year mortality rates across the elective and acute coronary syndromes and their associations with LV category are presented in Table 6 . Unadjusted mortality rates were lowest in those with good LV function and highest in those with poor LV function across all indications for PCI and at all-time points. Table 7 , both including and excluding patients presenting with cardiogenic shock or requiring circulatory support. Similar analyses following the IPW and propensity score matching are presented in Supplementary material online, Table S7A and B.
Discussion
In the current analysis of .230 000 PCI procedures undertaken in the UK over a period of 6 years, our data suggest a strong relationship between LV function and mortality outcomes following PCI, with worsening LV function associated with worse 30-day and longerterm mortality outcomes in both the elective and acute coronary syndrome setting. We also observe a differential impact of LV function on mortality outcomes across different indications for PCI, with the greatest adverse prognostic association between worsening LV function and mortality outcomes observed in patients undergoing PCI in the STEMI setting and least severe in the elective setting. Previous reports have also suggested that impaired LV function predicts mortality 1, 3, 4, 7, 8, 13 and MACE outcomes 1, 7 following PCI, although many were limited to only patients undergoing PCI in the elective setting, 1, 8, 11 and not specifically studying the differential impact of LV function on MACE or mortality across different PCI indications. 4, 7, 14 In keeping with other studies, we have observed that patients with reduced LV function undergoing PCI are older, more commonly diabetic, have a previous history of AMI and CABG and have a greater prevalence of cardiogenic shock. 1, 3, 4, 7, 8 Such adverse demographic features commonly found in patients with impaired LV function are known to contribute to un-favourable outcomes following PCI. However, even after adjustment for these adverse demographic features or following exclusion of patients with cardiogenic shock from analysis, reduced LV function is consistently associated with adverse mortality outcomes in the setting of both elective and acute coronary syndromes. Symptomatic heart failure and impaired LV function are known to be associated with adverse mortality outcomes in the medium and longer term. 15, 16 While the early separation of survival curves by LV function category and the significant impact on 30-day-mortality outcomes is consistent with a direct effect of LV dysfunction on peri-procedural risk, longer-term mortality rates may in part reflect the natural history of impaired LV function and heart failure.
The association between LV function and adverse mortality outcomes that we have observed, and the differential association particularly of poor LV function on mortality across different indications for PCI may be accounted for by a number of possible mechanisms and is likely to be multifactorial. Patients with impaired LV function are less able to tolerate haemodynamic or ischaemic complications in the setting of a PCI due to reduced physiological reserve, which may Impact of LV function on PCI outcomes explain the differential association particularly of severe LV function on mortality in different PCI settings with the highest independent risk observed in the STEMI cohort, where such haemodynamic and ischaemic complications are more prevalent and significant. In the longer term, patients with poor LV function are more likely to suffer progressive heart failure and arrhythmic deaths. Previous studies have shown an association between stent thrombosis and LV function, for example, Sardi et al. 7 reported definite/ probable stent thrombosis rates of 1.4% in patients undergoing PCI with good LV function and 6.0% in those patients with severe LV dysfunction (EF ,25%) and this relationship persisted following adjustment for baseline co-variates. Acute coronary syndromes, particularly STEMI have been shown to independently increase the risk of early (acute and subacute) stent thrombosis 3.6-fold and delayed (late and very late) almost four-fold compared with elective PCI patients. 17 Thus, the observed relationship between increased stent thrombosis with impaired LV function along with the observation that stent thrombosis is more prevalent in the ACS setting may partly explain the association between LV dysfunction and 30-day mortality outcomes, particularly its differential effects across syndromes with the greatest prognostic impact observed in the STEMI setting. While contemporary bleeding scores have not used LV function in their statistical models to derive bleeding risk scores, 18 a history of chronic heart failure is one of the key components of the National Cardiovascular Data CathPCI Registry (NCDR)-derived bleeding score 19 while others have shown that worsening LV function independently predicts major bleeding events post-PCI. 20 Major periprocedural bleeding rates vary according to the indication for which PCI is undertaken, increasing from 1.1% in patients with stable angina to 1.8 and 4.5% in NSTEMI and STEMI groups, respectively, in an analysis of the NCDR. 21 Such peri-procedural bleeding complications are associated with adverse clinical outcomes, including MI, stroke, and death 22 -24 which may contribute to the observation that the greatest mortality rates recorded were in patients with poor LV function undergoing PCI in the STEMI setting. Indeed, we show that unadjusted bleeding rates increase from 0.5% in patients undergoing PCI with good LV function to 1.5% in patients with poor LV function and LV function is independently associated with an increased risk of in-hospital bleeding complications in patients undergoing PCI. Left ventricular function features strongly as a predictor of adverse outcomes in contemporary risk stratification scores for patients undergoing PCI both for both mortality and MACE prediction. 9, 10 For example, inclusion of LV function as one of six clinical parameters to the anatomical SYNTAX score (to form the SYNTAX-2 score) significantly improved the models utility in predicting 4-year mortality outcomes following PCI or CABG compared with utilization of anatomical parameters alone as in the SYNTAX score. 10 Indeed, each 10% increase in LV function was independently associated with a 44% reduction in 4-year mortality following PCI and 16% reduction in 4-year mortality following CABG. It is therefore surprising, given the importance of LV function in contemporary risk stratification scores and our findings of the significant impact of LV function on mortality outcomes following PCI for all coronary syndrome indications that routine assessment of LV function has not been recommended prior to PCI in international guidelines. 25, 26 Our analysis has several strengths. The BCIS data set includes an almost complete collection of all PCI procedures performed in the UK. This data set of over 230 000 patients with LV function documented at baseline therefore reflects a national, real-world experience that includes high-risk patients encountered in daily interventional practice who are often excluded from randomized controlled trials and as such represents the largest analysis of the impact of LV function on PCI outcomes to date. Mortality tracking is undertaken by the MRIS using patients' NHS number that provides a unique identifier for any person registered with the NHS in England and Wales and hence provides accurate data regarding both short-and long-term data related to mortality outcomes.
Our analysis has a number of limitations, only 50% of patients who underwent PCI had formal assessment of LV function, hence the exclusion of patients without the assessment of LV function is a potential source of bias in determining patient outcomes, although the distribution of LV function is similar to those reported in similar analyses. 1, 4 We have also used IPW to account for missing data. Inverse probability weighting can be used to inflate the weight for subjects who are under-represented due to a large degree of missing data and have presented the results alongside our data derived using conventional cox regressions, with similar relationships between LV function and adverse outcomes documented. Finally, crude mortality rates and unadjusted death rates from 30-days to 5-years are of a similar order of magnitude in those patients with LV function data present and those with missing LV values (Supplementary material online, Table S3 ). Many operators do not routinely perform LV angiography prior to PCI, and echocardiographic or other means of assessing LV function may not have been performed prior to the procedure, supported by the observation that close to 50% of patients undergoing PCI in the UK do not have LV function documented on the BCIS data set. Furthermore, in those patients in whom LV function data are present, the BCIS data set does not provide information related to when the LV function was assessed and whether this was pre-procedurally, periprocedurally, or post-procedurally, which may introduce a potential source of bias. Inclusion of patients with cardiogenic shock in the current analysis who have in-hospital mortality rates as high as 30-50% 27 -29 may in part contribute to the adverse association between LV function and mortality outcomes, particularly for those with poor LV function in which the prevalence of cardiogenic shock was .10%. However, even following multivariate analysis in which cardiogenic shock presentation was included as a co-variate or following exclusion of patients with cardiogenic shock, the relationship between worsening LV function and adverse mortality outcomes across both the elective and acute coronary syndrome PCI setting persists. 
Impact of LV function on PCI outcomes
Finally, our analysis is of observational data and so cannot be used to infer a causal relationship between LV function and outcomes, because unmeasured confounders might account for some of the differences in outcomes observed despite the inclusion of multiple procedural and demographic factors in our multivariate regression analysis and propensity score matching. Thus, the previously reported association still holds in contemporary practice, in spite of the more widespread use of prognostically beneficial treatments.
In conclusion, our current analysis of over 230 000 contemporary PCI procedures in the drug-eluting stent era undertaken in the UK over a period of 6 years suggests a strong relationship between LV function and mortality outcomes following PCI, with worsening LV function independently predicting 30-day and longerterm mortality outcomes in both the elective and acute coronary syndrome setting. It supports historical reports of an association between reduced LV function and increased in hospital mortality. Our findings complement earlier studies and suggest that the assessment of LV function should be undertaken where possible prior to PCI especially considering the importance of LV function in contemporary risk stratification scores to enable more accurate quantification of risk. 
